Log In
Print
BCIQ
Print
Print this Print this
 

ALKS 3831

  Manage Alerts
Collapse Summary General Information
Company Alkermes plc
DescriptionCombination of ALKS 33, a mu opioid receptor (OPRM1; MOR) antagonist, and olanzapine, an antipsychotic monoaminergic receptor antagonist
Molecular Target Mu opioid receptor (OPRM1) (MOR)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSchizophrenia
Indication DetailsTreat schizophrenia
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today